亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Diabetes Imaging Agent

技術優勢: Improve early diagnosis, help monitor disease progression, provide tools to measure responsiveness to therapy and evaluate the efficiency of islet transplantation and graft survival.

技術應用: Method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. Diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.

詳細技術說明: D2 receptors (D2R) for dopamine were recently reported on rodent and human islets. University of California researchers propose to use a commercially available ligand with sub-nanomolar affinity and a high degree of specificity for D2R/D3R radiolabeled with fluorine-18 (half-life = 110 minutes) as a positron emission tomography (PET)-scanning agent to quantify changes in β-cell mass associated with diabetes mellitus. The fluorine-18 (18F) radioligand for dopamine D2 receptors (D2R) will be injected into diabetic patients. The radioligand will bind to the D2Rs in islets allowing the radioactive uptake by PET-CT scanning. Loss of beta cells will result in loss of radioligand binding to the pancreas. Since uptake of the radioligand in the liver is low, it may be feasible to detect small changes in the pancreas due to reduced background interference. The use of fluorine-18 as a radiolabel allows the use of the radioligand at facilities that do not have a cyclotron. Furthermore, the ligand is approved for human use making it eminently suitable as a diagnostic tool for T1DM.

*Abstract: The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.

*Principal Investigation: Name: Philippe Azam
Department:

Name: George Chandy
Department:

Name: Balu Easwaramoorthy
Department:

Name: Joseph Mantil
Department:

Name: Norah Milne
Department:

Name: Jogeshwar Mukherjee
Department:

Name: Ping Wang
Department:

附加資料: Patent Number: US20080319310A1
Application Number: US2008110135A
Inventor: Mukherjee, Jogeshwar | Chandy, George | Milne, Norah | Wang, Ping H. | Easwaramoorthy, Balu | Mantil, Joseph
Priority Date: 26 Apr 2007
Priority Number: US20080319310A1
Application Date: 25 Apr 2008
Publication Date: 25 Dec 2008
IPC Current: A61B0005055
US Class: 600420
Title: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Usefulness: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Summary: The method is useful for monitoring changes in beta cell mass in a patient, where the patient is at preclinical or clinical stage of diabetes such as Type I or Type II diabetes (all claimed).
Novelty: Non-invasive method for monitoring changes in beta cell mass in subject, involves detecting level of dopamine receptor in pancreas of subject

欲了解更多信息，請點擊這裡